AXNX - Axonics Modulation Technologies GAAP EPS of -$0.34 beats by $0.14 revenue of $70.4M beats by $7.42M

• Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q3 GAAP EPS of -$0.34 beats by $0.14 .
• Revenue of $70.4M (+50.1% Y/Y) beats by $7.42M .
• Sacral neuromodulation revenue was $56.9 million, of which $55.6 million was generated in the U.S. and the remainder in international markets.
• Bulkamid revenue was $13.5 million, of which $11.0 million was generated in the U.S. and the remainder in international markets.
• Gross margin was 72.8% in third quarter 2022 compared to 66.5% in the prior year period.
• Operating expenses were $67.6 million in third quarter 2022 and includes $8.2 million of non-cash costs for the change in fair value of contingent consideration related to the acquisition of Bulkamid. Operating expenses were $47.7 million in the prior year period.
• xcluding acquisition-related costs, adjusted operating expenses were $59.4 million in third quarter 2022.
• Net loss was $16.3 million in third quarter 2022 compared to net loss of $17.3 million in the prior year period.
• Cash, cash equivalents and short-term investments were $350 million as of September 30, 2022.

For further details see: